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Induced pluripotent stem cells (iPSCs) from type 1 long QT (LQT1) patients can differentiate into cardiomyocytes (CMs) including
ventricular cells to recapitulate the disease phenotype. Although optical recordings using membrane potential dyes to monitor
action potentials (APs) were reported, no study has investigated the disease phenotypes of cardiac channelopathy in association
with the cardiac subtype at the single-cell level. We induced iPSC-CMs from three control and three LQT1 patients. Single-cell
analysis using a fast-responding dye confirmed that ventricular cells were the dominant subtype (control-iPSC-CMs: 98%, 88%,
91%; LQT1-iPSC-CMs: 95%, 79%, 92%). In addition, LQT1-iPSC-ventricular cells displayed an increased frequency of early
afterdepolarizations (pvalue = 0 031). Cardiomyocyte monolayers constituted mostly of ventricular cells derived from
LQT1-iPSCs showed prolonged AP duration (APD) (pvalue = 0 000096). High-throughput assays using cardiomyocyte
monolayers in 96-well plates demonstrated that IKr inhibitors prolonged APDs in both control- and LQT1-iPSC-CM
monolayers. We confirmed that the optical recordings of APs in single cells and monolayers derived from control- and
LQT1-iPSC-CMs can be used to assess arrhythmogenicity, supporting the feasibility of membrane potential dye-based
high-throughput screening to study ventricular arrhythmias caused by genetic channelopathy or cardiotoxic drugs.
1. Introduction
Type 1 long QT syndrome (LQT1), a frequent type of con-
genital LQT syndrome (cLQTS) [1], is caused by a reduction
of slow delayed rectifier K+ current (IKs) and is associated
with a loss-of-function mutation in the KCNQ1 gene [2].
KCNQ1 A341V is known as one of the most frequent and
severe KCNQ1 mutations [3]. Its coexpression with
wild-type KCNE1, a beta subunit of the IKs channel, causes
a pathological reduction of IKs [4], suggesting the impor-
tance of building physiological conditions to recapitulate
the pathology in vitro. Human induced pluripotent stem
cell-derived cardiomyocytes (hiPSC-CMs) were shown to
remodel ion channels that regulate the electrophysiological
activity of the human heart and to successfully recapitulate
the LQT1 phenotype [5–8].
Previous papers related to cLQTS patient-specific
hiPSC-CMs verified the disease phenotype by using either
the manual patch clamp method alone [5, 7] or in combina-
tion with the microelectrode array (MEA) system [6, 8].
However, the field potential duration (FPD), which reflects
QT on electrocardiograms (ECG), of ventricular hiPSC-CM
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monolayers is longer than that of atrial iPSC-CMs when
using the MEA system [9], suggesting a high proportion of
ventricular hiPSC-CMs is required to analyze ventricular
arrhythmic disease. Patch clamp analysis is standard for clas-
sifying the cardiac subtype, but it requires much time and
expertise [10]. Automated patch clamp techniques may
resolve these drawbacks, but they cause cells to produce
spontaneous action potentials (APs) that are erratic due to
enzymatic treatment immediately before the analysis [11].
FluoVolt (FV) is a new membrane potential VF2.4.CI
dye [12, 13]. It modulates photo-induced electron transfer
(PeT) from an electron donor to a fluorophore through a
synthetic molecular wire [12, 14] and responds on a micro-
second timescale, which makes it faster than genetically
encoded voltage indicators [15, 16]. Moreover, it has a
higher fluorescence ratio (about 20% ΔF/F per 100mV
greater) and lower phototoxicity than electrochromic dyes
such as di-4-ANEPPS [12, 17], enabling classification of
the subtype of single cardiomyocytes [18].
FV and VF2.1.Cl have been used to analyze APs from
iCell® cardiomyocyte monolayers or type 3 LQTS-iPSC-CM
monolayers and also drug effects on multiwell plate readers
[19, 20]. However, the proportion of ventricular-type cells
in those monolayers was not examined. Since arrhythmo-
genic change occurs in ventricular cells in LQTS, it is crucial
to investigate the electrophysiological properties of this
specific subtype.
In the present study, we propose a new method that
incorporates FV and combines optical measurements of
the membrane potential of single cardiomyocytes and in car-
diac monolayers to identify the subtype and associate the
subtype with the cardiomyocyte properties. We show the
effectiveness of this method for modeling LQT1 using
patient hiPSC-CMs.
2. Materials and Methods
2.1. Generation of Human iPS Cells from Three Type 1 LQTS
Patients. This study was approved by the Ethics Committees
of the Graduate School of Medicine Kyoto University and
the Kyoto University Hospital. Written informed consent
was obtained from the patients in accordance with the Dec-
laration of Helsinki. LQT1-iPSCs were generated from three
patients using episomal vectors as described previously [21].
Three iPSC lines derived from healthy donors (201B7 [22],
409B2 [21], and 692D2 [23]) were used as control iPSCs.
Human iPSCs were maintained on STO feeder layers cul-
tured with primate ES cell medium (ReproCell, Yokohama,
Kanagawa, Japan), as previously described [22].
2.2. Cardiac Differentiation and Fluorescence-Activated Cell
Sorting. Human iPSCs were differentiated by forming
embryoid bodies (EBs), as previously described [24, 25]
(see Supplementary Materials for further details). On day
29, EBs were dissociated and dispersed onto a fibronectin
(Sigma-Aldrich, St Louis, MO, USA)-coated 6 cm dish. On
the following day, seeded cells were collected by Accumax
(Innovative Cell Technologies, San Diego, CA, USA) for 10
minutes and subjected to fluorescence-activated cell sorting
(FACS) (Aria II, BD Biosciences, San Jose, CA, USA). To
purify cardiomyocytes, SIRPa-positive and lineage (CD31,
CD49a, CD140b, CD90, or TRA-1-60)-negative cells were
sorted [26] and cryopreserved with STEM-CELLBANKER
(Nippon Zenyaku Kogyo, Koriyama, Japan) at −80°C. A
few weeks later, the cryotubes were transferred to a liquid
nitrogen storage tank.
2.3. Quantitative Polymerase Chain Reaction (qPCR). Total
RNA was extracted after FACS using QIAzol Lysis Reagent
(QIAGEN, Hilden, Germany). qRT-PCR was performed
with TaqMan gene expression assays (Thermo Fisher
Scientific, Waltham, MA, USA). For further details, see
Supplementary Materials.
2.4. Thawing Frozen iPSC-CMs. For perforated patch clamp
recording, the cryotubes were thawed in a 37°C water
bath, centrifuged at 300 g for 5min, and seeded on
fibronectin-coated No. 2 cover glass (Matsunami, Osaka,
Japan) filled with StemPro 34 SFM (Thermo Fisher Scientific)
containing buffer and 10ng/ml VEGF. Five to ten days after
seeding, the cells were subjected to patch clamp experiments.
2.5. Current Clamp Recording. Perforated whole-cell patch
was performed with current clamp mode using amphoteri-
cin B (Sigma-Aldrich), an Axopatch 200B amplifier (Molec-
ular Devices, Sunnyvale, CA, USA), and pCLAMP software
(Molecular Devices). Maximum diastolic potential (MDP),
AP amplitude (APA), and action potential duration (APD)
at 90% repolarization (APD90) were calculated from the
average AP of 10 consecutive and stable waves in 1Hz pac-
ing mode with pCLAMP software. For detailed protocols,
see Supplementary Materials.
2.6. Voltage Clamp Recording. IKs currents were recorded
from single cardiomyocytes with the ruptured whole-cell
patch clamp technique. IKs was calculated by subtracting
the currents after perfusion with extracellular solution con-
taining 30μM (-)-[3R,4S]-chromanol 293B (Tocris Biosci-
ence, Bristol, UK) from the currents before perfusion. IKs
currents were elicited by depolarizing steps from a holding
potential of −40mV to −20, 0, 20, and 40mV for 4 s. This
was followed by a 2 s repolarization phase. For detailed pro-
tocols, see Supplementary Materials.
2.7. Seeding High-Density iPSC-CM Monolayer. 2μl of
50μg/ml fibronectin was placed on a 35mm diameter glass
bottom dish (Matsunami), or 5μl was placed on a 96-well
plate with clear flat bottom wells (Corning, Corning, NY,
USA). One hour later, fibronectin was aspirated, and a 2μl
bead of thawed 4× 104 iPSC-CM suspension was placed on
the 35mm dish or a 5μl bead of thawed 5× 104 iPSC-CM
suspension was placed on the 96-well plate. After another
one-hour incubation, the appropriate volume of media was
added gently. The dish or plate was incubated at 37°C, 5%
CO2. The composition of the media was the same on days
7 to 29. Medium was exchanged every 2 to 3 days.
2.8. Loading of FV. When loading FluoVolt (FV; Thermo
Fisher Scientific), the medium was exchanged with modified
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Tyrode’s solution and FV (0.1% volume). Pluronic surfac-
tants were not used in this study. Twenty minutes after load-
ing, the medium was refreshed with modified Tyrode’s
solution and used in each assay.
2.9. Optical Recording of APs from Single Cells or
Cardiomyocyte Monolayers. Cells were imaged in a 35mm
diameter glass bottom dish at 37°C and modified Tyrode’s
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Figure 1: Type1 long QT syndrome family background and cardiac differentiation from human iPSCs. (a) Family pedigree. The squares
indicate males and the circles indicate females. Closed symbols mark patients confirmed by their DNA sequences. Hexagrams mark
members who have a syncope history. The QTc values of three patients before taking a beta-blocker are stated. (b) ECG of II-2 in
Figure 1(a) before the patient started taking a beta-blocker. (c) Sanger sequencing of the three patients and one control. (d) Schematic
figure of KCNQ1 protein. The black circle indicates the mutation site within the transmembrane region. The lower side locates
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Figure 2: Continued.
4 Stem Cells International
Subarray images were recorded every 8ms in single cells or
every 4ms in monolayer using AquaCosmos software
(Hamamatsu Photonics). The regions of interest (ROIs) in
the monolayers were defined as whole pixels of 512× 32 at
1Hz pacing. Graphing and calculation of APD90 were per-
formed with OriginPro 2016 (OriginLab, Northampton,
MA, USA). For further details, see Supplementary Materials.
2.10. Optical Recording of APs from Cardiomyocyte Monolayers
on a High-Throughput Plate Reader. The FDSS/μCell imaging
platform (Hamamatsu Photonics) was used. The LED cur-
rent was set to 300mA. An output excitation wavelength
was used with standard settings of 492 BP 20nm and emis-
sion filter 540AF40 (Omega Optical, Brattleboro, VT, USA).
Binning was set to 4×4, and the measurement interval was
every 4ms. Cardiomyocyte monolayers 7–10 days after seed-
ing on each well were stimulated at 1Hz with 1ms depolar-
izing pulses at 10V. Analysis of APD90 was performed with
FDSS Waveform Analysis software for cardiomyocytes
(U8524-12; Hamamatsu Photonics).
2.11. Movie. Blinking monolayers were recorded with
AquaCosmos software at 30 fps.
2.12. Statistical Analysis. All statistical analyses were verified
with an unpaired t-test using Excel 2016 (Microsoft,
Redmond, WA, USA). Values considered statistically signif-
icant are denoted as ∗p < 0 05 and ∗∗p < 0 005 in the figures.
3. Results
3.1. Establishment of Three LQT1 Patient-Derived iPS Cell
Lines. We selected three LQT1 patients as donors for the
iPSC derivation. One of the donors was a 50-year-old
woman (II-2 in Figure 1(a)) who experienced presyncope
several times when she was in junior high school and under-
went recurrent syncope in her thirties. She showed promi-
nent QT prolongation in resting ECG (Figure 1(b)) and
exercise ECG. The other donors were her two daughters
whose QT intervals were prolonged according to school
medical examinations. Genetic testing diagnosed the mother
and two daughters as type 1 long QT syndrome with KCNQ1
A341V mutation (c.1022C>T) (Figure 1(c)). The mutation is
located at the transmembrane region in segment 6 near the
pore of the IKs channel (Figure 1(d)) and is reported as
one of the severest types of LQT1 [3]. Medical therapy
(beta-blockade) and lifestyle measures were sufficient to pre-
vent recurrent events in the three patients. Five of the six
family members positive for KCNQ1 mutation experienced
syncope, and the sixth (III-1 in Figure 1(a)) did not. All car-
riers showed QTc prolongation on ECG.
iPSCs were generated from the peripheral blood of the
three patients using a nonviral method [21] and were differ-
entiated into cardiomyocytes via EB formation [24, 25]
(Figure 1(e)). There was no significant difference in the
expression of genes that affect APD between control- and
LQT1-iPSC-CMs (Supplementary Figure 1).
3.2. Patch Clamp Analysis. Ventricular-type cardiomyocytes
derived from the three control- and three LQT1-iPSC lines
were subject to current clamp recordings (Figure 2(a)).
Although there was no significant difference in MDP or
APA, there was a significant difference in APD90 during pacing
at 1Hz between control- and LQT1-iPSC-CMs (Figure 2(b)) (p
value, 0.0026). In addition, voltage clamp recordings revealed
much smaller chromanol 293B-sensitive IKs currents from
LQT1-iPSC-CMs than controls (Figures 2(c) and 2(d)).
3.3. Action Potentials Recorded by FV Dye in Single






















Figure 2: Patch clamp analysis of cardiomyocytes from control- and LQT-iPSC lines. (a) Representative APs of 1Hz paced a
control-iPSC-CM and an LQT-iPSC-CM from II-2 in Figure 1(a). Ten consecutive waves are shown. (b) MDP, APA, and APD90 from
cardiomyocytes derived from the six lines: 201B7 (n = 6), 409B2 (n = 5), 692D2 (n = 6), LQT1A1 (n = 5), LQT1B1 (n = 5), and LQT1C1
(n = 7). Data are represented as means± SEM; ∗∗p < 0 005. (c) Representative current traces from control- and LQT1-iPSC-CMs. Upper,
the protocol in current clamp recording. Middle, representative traces before and after perfusion with 3R4S-chromanol 293B
(30 μmol/l). Lower, 3R4S-chromanol 293B-subtraction. (d) I-V plots of IKs at the end of the depolarizing step. 692D2 (control)
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based on the APs of single cells obtained by FV (Figures 3(a)
and 3(b) and Supplementary Figure 2). Ventricular, atrial,
and nodal cardiomyocytes were defined as APD90/APD50<1.4,
1.7<APD90/APD50, and 1.4<APD90/APD50<1.7, respec-
tively, as previously reported (Supplementary Figure 2) [27,
28]. We labeled ventricular cells whose APD was more than 1
second as “ventricular cells with long APD.” These cells
were more frequently observed among LQT-iPSC-CMs
(Figures 3(b) and 3(c)) than control-iPSC-CMs (Figures 3(a)
and 3(c)). The ventricular-like cardiomyocytes in control and
LQT1-iPSC-CMs constituted the major population (201B7
(control), 98%; 409B2 (control), 88%; 692D2 (control), 90%;
LQT1A1 (mother), 95%; LQT1B1 (elder sister), 79%; and
LQT1C1 (younger sister), 93%) (Figure 3(c)). The frequencies
of ventricular cells with long APD in control-iPSC-CMs
(201B7, 16%; 409B2, 17%; and 692D2, 19%) were lower than
those in LQT1-iPSC-CMs (LQT1A1, 50%; LQT1B1, 31%;
and LQT1C1, 32%) (Figure 3(c)). Intriguingly, we observed
more early afterdepolarizations (EADs) in LQT1-iPSC-CM
populations than in control-iPSC-CM populations
(Figures 3(d) and 3(e)) (p value, 0.031).
3.4. Action Potentials Recorded by FV in hiPSC-CM
Monolayers. We next measured the APDs during pacing in
high-density cardiomyocyte culture (Figure 4(a)). Ten con-
secutive waves after dye loading were averaged (Figure 4(b)
and Supplementary Movie). APD90 from LQT1-iPSC-CMs
was significantly longer than that from control-iPSC-CMs
(Figure 4(c)) (p value, 0.000096).
3.5. APD Measured by FV on High-Throughput Plate Reader.
We next measured hiPSC-CM monolayers by FV in a higher
throughput system consisting of a 96-well plate. The APs on
monolayers were stable before and after 1Hz pacing
(Figure 5(a)). The APD90 averaged from 10 consecutive
waves of LQT1B1-iPSC-CMs was longer than that from con-
trol-iPSC-CMs, and cisapride prolonged the APD90 of cardi-
omyocytes derived from both iPSC groups (Figure 5(b)). In
addition, we administered a beta stimulant to mimic the
conditions under exertional or emotional stress, in which
the disease phenotypes are more prominent [5, 6]. In the
presence of 100nM isoproterenol (ISP), we assessed the effect
of several agents on drug-induced long QT syndrome
(diLQTS). Erythromycin and cisapride prolonged APD90 in
both iPSC-CM groups under ISP, but the APD90 of
LQT-iPSC-CMs was consistently higher at all concentrations
(Figures 5(c) and 5(d)). These findings support the applicabil-
ity of the membrane dye system to high-throughput-based
drug discovery and toxicology testing.
4. Discussion
The proportion of a cardiac subtype in iPSC-CMs or cardiac
monolayers and the AP parameters were reported to vary
depending on the culture duration [29], suggesting the
importance of a high proportion of the ventricular subtype
when modeling the disease phenotypes of ventricular
arrhythmias. In this study, we have proposed a simple
method that uses FV to measure both single cardiomyocytes
and cardiac monolayers derived from normal and
LQT1-iPSCs. Optical recordings of single cardiomyocytes
identified the cardiac subtypes of each cells and confirmed
their variable electrophysiological properties (Figures 3(a)–
3(c)), which was consistent with previous reports of a genet-
ically encoded membrane potential sensor [15, 16]. High
electrophysiological variability of single iPSC-CMs warrants
assessment of a large population of ventricular cells for
modeling ventricular arrhythmia. Our results demonstrated































Figure 3: AP measurements of single cells using a membrane potential dye. (a) Examples of AP waves from control (409B2) measured by the
dye. ROIs (1)–(5) are ventricular type. ROI (5) (green wave) shows long APD. (b) Examples of AP waves from LQT1B1. ROIs (1)–(4) are
ventricular type with long APD. ROI (4) (purple wave) shows EADs. ROI (5) (green wave) is nodal type. (c) Proportion of subtypes in 3
control- and 3 LQT1-iPSC-CMs: 201B7 (n = 128), 409B2 (n = 41), 692D2 (n = 92), LQT1A1 (n = 192), LQT1B1 (n = 101), and LQT1C1
(n = 202). Ventricular-type cells predominate in all six lines. (d) Representative EADs in a ventricular-type cell from LQT1B1. The EADs
were defined as over 20% of the AP amplitude. Arrows show EADs. (e) Occurrence ratio of EADs in ventricular cardiomyocytes from the
six lines. The number of ventricular cells was used as the denominator; ∗p < 0 05.
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subtypes and assess the electrophysiological properties of a
large number of iPSC-CMs simultaneously.
The monolayered cells successfully reduced the varia-
tions of APD when synchronized with electrical stimulation
at a constant frequency. As previously reported, FPD, an
electrophysiological parameter highly correlated with APD
[30], of ventricular hiPSC-CM monolayers was longer than
that of atrial iPSC-CM monolayers [9], suggesting that the
high proportion of the ventricular subtype would be appro-
priate for analyzing the APs of LQT-iPSC-CM monolayers
and diLQTS models. Combined with single cell-based iden-
tification of cardiac subtypes, our optical recordings con-
firmed that iPSC-CM monolayers composed mainly of
ventricular cells recapitulated the prolonged AP duration
of cLQTS and diLQT. In addition, this system was applicable
to high-throughput analysis to investigate the response
to drugs.
Although conventional styryl voltage-sensitive dyes, such
as di-4-ANEPPS and di-8-ANEPPS, have the ability to
respond quickly to voltage changes, they have low sensitivity
and nonnegligible phototoxicity [17, 31]. FV and di-4-
ANBDQBS, a near-infrared fluorescent voltage-sensitive dye,
can precisely track the transmembrane voltage with lower
photodynamic damage than di-4-ANEPPS [12, 32, 33].
Furthermore, FV has been used for a high-throughput
screening [19].
(a)






























Figure 4: AP measurements in a cardiomyocyte monolayer. Data are represented as means± SEM. (a) An example phase contrast image of
the monolayer culture. Scale bar, 500μm. (b) Representative AP of a paced control-iPSC-CM monolayer. APD90 was calculated from the
average of 10 consecutive waves. (c) APD90 from 3 control- and 3 LQT-iPSC-CM monolayers: 201B7 (n = 3), 409B2 (n = 3), 692D2 (n = 3
), LQT1A1 (n = 3), LQT1B1 (n = 3), and LQT1C1 (n = 3). LQT-iPSC-CMs showed longer APD than controls; ∗∗p < 0 005.
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ArcLight is a genetically encoded sensor of membrane
potential that has brighter fluorescence and negligible pho-
totoxicity and has been used to study cardiomyocytes
derived from human embryonic stem cells [15] and LQT2
iPSC-CMs [16]. However, the recorded APs do not agree
with those from patch clamp techniques due to the slow
temporal response of ArcLight [34]. VSFP-CR [35], a deriv-
ative of VSFP2.3 [36], was previously combined with
subtype-specific marker genes (MLC2v, SLN, and SHOX2)
to analyze the APs of three iPSC-CM subtypes [37].
Although genetically encoded voltage indicators enabled
promotor-specific voltage response, it takes much time to
establish the genetically modified cell lines stably. On the
other hand, FV can be rapidly used with many cell lines, as
it needs only 20min loading.
diLQTS, which is an acquired LQTS, is mainly caused by
blockage of the IKr channel and is more frequent than cLQTS.
It is well known that the mutation of genes responsible for
cLQTS could contribute to an increased risk of diLQTS [38,
39]. diLQTS has a similar mutation rate as cLQTS for the three
major genes responsible for cLQTS [40], leading to the
hypothesis that type 1 cLQTS patient-derived iPSC-CMs are
appropriate for studying drugs that cause QT prolongation
by blocking IKr current. In the present study, we used FV to
identify drugs that prolonged QT in LQT1-iPSC-CM and
control-iPSC-CM monolayers in a high-throughput manner
(Figures 5(b)–5(d)).
Despite our encouraging results, it should be noted
that FV has some limitations because the measured APs
are based on a relative scale. Nor do the APs provide
MDP or APA values, unlike patch clamp analysis. Further-
more, hiPSC-CMs are heterogeneous in electrophysiologi-
cal properties, including their APDs and automaticities,
making it difficult to measure the APs of paced cardio-
myocytes simultaneously. Thus, in FV experiments, APDs
in single cells were obtained from unpaced cells with
different beating frequencies. Heterogeneity of the induced
cardiomyocytes may also cause variations in the
recordings. Studies have investigated ways to mature
hiPSC-CMs [41, 42], which could reduce the heterogeneity
and thus contribute to more robust and precise high-
throughput screening.
Although many reports have used the AP morphology-



























































Figure 5: AP measurements in cardiomyocyte monolayers using a high-throughput plate reader. (a) Representative AP waves on a 96-well
plate. Pacing at 1Hz starts 10 s after recording. (b) Cisapride prolonged APD90 of both control- and LQT1-iPSC-CMs; 692D2 (control) (n = 3
), LQT1B1 (n = 5). (c) Cisapride prolonged APD90 of both control- and LQT1-iPSC-CMs with 100 nM isoproterenol; 692D2 (n = 5), LQT1B1
(n = 3). (d) Erythromycin prolonged APD90 of both control- and LQT1-iPSC-CMs with 100 nM isoproterenol; 692D2 (n = 4), LQT1B1 (n = 3
). LQT-iPSC-CMmonolayers in 300 nM and 1000 nM cisapride were not synchronized at 1Hz pacing. Data are represented as means± SEM;
∗∗p < 0 005, ∗p < 0 05.
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has recently been argued that APmorphology is not a reliable
indicator [45, 46]. Future methods that can distinguish
cardiomyocyte subtypes induced from pluripotent stem cells
would contribute to measuring long APD in LQT-iPSC-CMs
more precisely.
5. Conclusions
In summary, using an FV-based optical measurement sys-
tem, we successfully identified ventricular-type cells as the
major population in cardiac subtypes and found that they
have a higher frequency of APD prolongation and EAD
when derived from LQT1 patient iPSCs. Further, monolayers
with this major population were suitable for analyzing
two-dimensional AP in LQT-iPSC-CMs and diLQTS models
in a high-throughput manner.
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